Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-21-012661

Chief Business Officer sold 15,000 shares at an average $35.49 ($532,352)

  • Chief Business Officer acquired 15,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Beaurang Pierre · Chief Business Officer

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2021-02-18 Exercise or conversion : show line 1 in the form +9,107 $0.84 $7,650 9,107 D
2021-02-18 Exercise or conversion : show line 2 in the form +3,797 $7.26 $27,566 12,904 D
2021-02-18 Exercise or conversion : show line 3 in the form +2,096 $9.57 $20,059 15,000 D
2021-02-18 Sale : show line 4 in the form −2,647 $34.19 $90,496 12,353 D
2021-02-18 Sale : show line 5 in the form −4,553 $35.02 $159,454 7,800 D
2021-02-18 Sale : show line 6 in the form −6,400 $35.99 $230,328 1,400 D
2021-02-18 Sale : show line 7 in the form −1,000 $36.92 $36,924 400 D
2021-02-18 Sale : show line 8 in the form −400 $37.88 $15,150 0 D
Open-market sales · 15,000 sh · avg $35.49 · $532,352

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2021-02-18 Exercise or conversion : show line 9 in the form Employee Stock Option (right to buy) −9,107 $0.84 2026-01-27 9,107 14,226 D
2021-02-18 Exercise or conversion : show line 10 in the form Employee Stock Option (right to buy) −3,797 $7.26 2030-02-26 3,797 72,869 D
2021-02-18 Exercise or conversion : show line 11 in the form Employee Stock Option (right to buy) −2,096 $9.57 2030-06-27 2,096 14,678 D
Loading xslF345X03/doc4.xml…